Real-time single-cell profiling from FFPE samples to inform treatment strategies in advanced solid tumors

This poster presents the retrospective SPARK analysis, conducted in collaboration with the Centre Léon Bérard, showing that OneMap™ single-cell transcriptomic profiling can generate clinically interpretable data from archived FFPE samples in patients with advanced solid tumors. Across 16 patients, OneMap produced interpretable multicellular profiles in all samples and identified additional potentially clinically relevant therapeutic hypotheses in 7/16 patients (44%), including tumor-specific target expression and tumor microenvironment features. Presented at ESMO-MAP, these results highlight OneMap’s potential to complement standard molecular profiling and have led to the launch of a prospective SPARK study with Centre Léon Bérard, evaluating its use in real-time Molecular Tumor Board decision-making.